| |
| |
|
| Insider
Information: |
Fridriksdottir Hafrun |
| Relationship: |
Executive VP, Global R&D |
| City: |
Parsippany |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
8,301 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,358,244 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
8,301 |
|
|
| Total
Value |
$1,358,244 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 4.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Allergan plc |
AGN |
SVP, GLOBAL R&D |
2014-05-09 |
6,914 |
2013-10-01 |
0 |
Premium* |
|
|
Teva Pharmaceutical Industries L... |
TEVA |
Executive VP, Global R&D |
2022-05-17 |
1,387 |
2018-03-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
49 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AGN |
Allergan plc |
SVP, GLOBAL R&D |
• – – |
2013-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,645 |
5,645 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,165 |
4,510 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,432 |
7,942 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,012 |
7,399 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-11-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,711 |
9,762 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,640 |
13,469 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,353 |
17,179 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,165 |
16,503 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,012 |
17,106 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-11-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,133 |
24,883 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,640 |
25,213 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,120 |
38,874 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,203 |
56,533 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,014 |
46,075 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
67,852 |
129,533 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,120 |
61,681 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,355 |
105,392 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,682 |
124,976 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,905 |
82,969 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,884 |
111,338 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,121 |
57,533 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,682 |
73,099 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
70,393 |
117,882 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,764 |
135,028 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-03-17 |
4 |
AS |
$7.16 |
$3,682 |
D/D |
(514) |
45,561 |
0 |
% |
|
49 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
